DICE Therapeutics
Yu Su, CPA brings a wealth of experience to their current role as an Accounting Manager at DICE Therapeutics, where they have been employed since December 2021. Prior to joining DICE Therapeutics, Yu Su worked as a Senior Tax Consultant at Deloitte from August 2019 to April 2021. Before that, they held the position of Tax Supervisor at Seiler LLP from August 2017 to August 2019. Yu Su's career in accounting began as a Senior Accountant at B & R Accounting, where they worked from July 2014 to August 2017.
Yu Su, CPA has a Master of Science (M.S.) degree in Accountancy from San Francisco State University, which was obtained from 2012 to 2014. Prior to that, he/she obtained a Bachelor of Arts (B.A.) degree in Business Administration and Management, General from Maharishi International University from 2010 to 2012. In 2008 to 2010, Yu Su studied International Accounting and Finance at Capital University of Economics and Business, but the degree obtained during that time is not specified. Yu Su is also a Certified Public Accountant, although the specific institution and date of certification are not provided.
DICE Therapeutics
At DICE Therapeutics, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. We believe that such pills will be widely appreciated by patients and doctors alike, as they provide a lower bar to entry than biologics, and as oral medicines can easily be co-formulated with other efficacious drugs. The combination of our core technology with additional, unique biophysical insights has enabled DICE to target protein-protein interactions with small molecules. In doing so, DICE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is currently progressing through IND-enabling studies. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline.